ALSO NOTED: Wockhardt gets OK for Zithromax copy; Depomed's gabapentin formula passes Phase II;

> Wockhardt got the FDA nod to sell a copycat form of Pfizer's Zithromax, an antibiotic. Report

> Depomed announced that its in-development extended release form of gabapentin showed efficacy against menopausal hot flashes in a Phase II trial. Report

> Nektar Therapeutics' COO Dr. Hoyoung Huh stepped down to take a CEO job at BiPar Sciences; separately, the company said it would cut 150 employees, or about 20 percent of its workforce. Release | Release

> A new study found that the epilepsy med Trileptal didn't prevent migraines; the drug and its ilk have been used against migraine for decades. Report

> An Alabama attorney asked a jury to award the state $40 million in compensatory damages in a fraud lawsuit against AstraZeneca, which alleges that the company inflated its prices. Report

> The FDA has told Adolor and GSK that it will take three more months to review Entereg, a anti-constipation drug candidate. Report

> Italy's Newron Pharmaceuticals has U.K.-based Hunter-Fleming, a company that's developing therapies for neurodegenerative and inflammatory disorders. Report

> An article in the Indianapolis Star details Lilly's development program for MBP9289, a multiple sclerosis drug offering hope to both patients and a drug developer that hasn't launched a new drug for humans since 2005. Report

> Rumors are swirling that Sanofi-Aventis may be making a bid for Oxford BioMedica, a U.K.-based developer of gene-based medicines. Report

And Finally... Just in time for Valentine's Day, more good news about chocolate's health effects. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.